122 related articles for article (PubMed ID: 12150168)
1. Observed costs and health care use of children in a randomized controlled trial of pneumococcal conjugate vaccine.
Ray GT; Butler JC; Black SB; Shinefield HR; Fireman BH; Lieu TA
Pediatr Infect Dis J; 2002 May; 21(5):361-5. PubMed ID: 12150168
[TBL] [Abstract][Full Text] [Related]
2. Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in China.
Shen K; Wasserman M; Liu D; Yang YH; Yang J; Guzauskas GF; Wang BCM; Hilton B; Farkouh R
PLoS One; 2018; 13(7):e0201245. PubMed ID: 30044865
[TBL] [Abstract][Full Text] [Related]
3. Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children.
Lieu TA; Ray GT; Black SB; Butler JC; Klein JO; Breiman RF; Miller MA; Shinefield HR
JAMA; 2000 Mar; 283(11):1460-8. PubMed ID: 10732936
[TBL] [Abstract][Full Text] [Related]
4. Assessing costs and cost effectiveness of pneumococcal disease and vaccination within Kaiser Permanente.
Black S; Lieu TA; Ray GT; Capra A; Shinefield HR
Vaccine; 2000 Dec; 19 Suppl 1():S83-6. PubMed ID: 11163469
[TBL] [Abstract][Full Text] [Related]
5. Pneumococcal conjugate vaccine for young children.
Selman S; Hayes D; Perin LA; Hayes WS
Manag Care; 2000 Sep; 9(9):49-52, 54, 56-7 passim. PubMed ID: 11116663
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness analysis of infant pneumococcal vaccination with PHiD-CV in Korea.
Zhang XH; Leeuwenkamp O; Oh KB; Lee YE; Kim CM
Hum Vaccin Immunother; 2018 Jan; 14(1):85-94. PubMed ID: 29115905
[TBL] [Abstract][Full Text] [Related]
7. Economic burden of pneumococcal infections in children under 5 years of age.
Ceyhan M; Ozsurekci Y; Aykac K; Hacibedel B; Ozbilgili E
Hum Vaccin Immunother; 2018 Jan; 14(1):106-110. PubMed ID: 28922054
[TBL] [Abstract][Full Text] [Related]
8. The cost-effectiveness of pneumococcal conjugate vaccination in Australia.
Butler JR; McIntyre P; MacIntyre CR; Gilmour R; Howarth AL; Sander B
Vaccine; 2004 Mar; 22(9-10):1138-49. PubMed ID: 15003641
[TBL] [Abstract][Full Text] [Related]
9. A pharmacoeconomic evaluation of 7-valent pneumococcal conjugate vaccine in Canada.
Lebel MH; Kellner JD; Ford-Jones EL; Hvidsten K; Wang EC; Ciuryla V; Arikian S; Casciano R
Clin Infect Dis; 2003 Feb; 36(3):259-68. PubMed ID: 12539065
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of second generation pneumococcal conjugate vaccines in Norway.
Robberstad B; Frostad CR; Akselsen PE; Kværner KJ; Berstad AK
Vaccine; 2011 Nov; 29(47):8564-74. PubMed ID: 21945264
[TBL] [Abstract][Full Text] [Related]
11. National impact of universal childhood immunization with pneumococcal conjugate vaccine on outpatient medical care visits in the United States.
Grijalva CG; Poehling KA; Nuorti JP; Zhu Y; Martin SW; Edwards KM; Griffin MR
Pediatrics; 2006 Sep; 118(3):865-73. PubMed ID: 16950975
[TBL] [Abstract][Full Text] [Related]
12. Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.
Kuhlmann A; von der Schulenburg JG
Eur J Health Econ; 2017 Apr; 18(3):273-292. PubMed ID: 26905404
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of conjugate pneumococcal vaccination in Singapore: comparing estimates for 7-valent, 10-valent, and 13-valent vaccines.
Tyo KR; Rosen MM; Zeng W; Yap M; Pwee KH; Ang LW; Shepard DS
Vaccine; 2011 Sep; 29(38):6686-94. PubMed ID: 21745516
[TBL] [Abstract][Full Text] [Related]
14. Preferences and willingness to pay for health states prevented by pneumococcal conjugate vaccine.
Prosser LA; Ray GT; O'Brien M; Kleinman K; Santoli J; Lieu TA
Pediatrics; 2004 Feb; 113(2):283-90. PubMed ID: 14754939
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of universal infant vaccination with 7vPCV in Hong Kong.
Lee KK; Rinaldi F; Chan MK; Chan ST; So TM; Hon EK; Lee VW
Value Health; 2009; 12 Suppl 3():S42-8. PubMed ID: 20586981
[TBL] [Abstract][Full Text] [Related]
16. A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.
Asensi F; De Jose M; Lorente M; Moraga F; Ciuryla V; Arikian S; Casciano R; Vento M
Value Health; 2004; 7(1):36-51. PubMed ID: 14720129
[TBL] [Abstract][Full Text] [Related]
17. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
18. [Cost-effectiveness analysis of pneumococcal vaccination in Spain].
Morano R; Pérez F; Brosa M; Pérez Escolano I
Gac Sanit; 2011; 25(4):267-73. PubMed ID: 21640443
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness analysis of routine pneumococcal vaccination in the UK: a comparison of the PHiD-CV vaccine and the PCV-13 vaccine using a Markov model.
Delgleize E; Leeuwenkamp O; Theodorou E; Van de Velde N
BMJ Open; 2016 Nov; 6(11):e010776. PubMed ID: 27903558
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of 13-valent pneumococcal conjugate vaccine in Switzerland.
Blank PR; Szucs TD
Vaccine; 2012 Jun; 30(28):4267-75. PubMed ID: 22521287
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
